Showing posts with label hypersensitivity. Show all posts
Showing posts with label hypersensitivity. Show all posts

Tuesday, September 24, 2013

0 Management of Insect Sting Hypersensitivity: An Update


Logo of aair








Allergy Asthma Immunol Res. 2013 May; 5(3): 129–137.

Published online 2013 February 25. doi:  10.4168/aair.2013.5.3.129




PMCID: PMC3636446





Management of Insect Sting Hypersensitivity: An Update








Abstract



Reactions to Hymenoptera insect stings are common. While most are self-limited, some induce systemic allergic reactions or anaphylaxis. Prompt recognition, diagnosis, and treatment of these reactions are important for improving quality-of-life and reducing the risk of future sting reactions. This review summarizes the current recommendations to diagnose and treat Hymenoptera sting induced allergic reactions and highlights considerations for various populations throughout the world.


Formats:




Keywords: Hymenoptera allergy, venom immunotherapy, sting-induced anaphylaxis, insect sting allergy, insect sting hypersensitivity




Sunday, September 22, 2013

0 Progress in understanding hypersensitivity drug reactions: an overview. Full text.


Current Opinion in Allergy & Clinical Immunology:

August 2012 – Volume 12 – Issue 4 – p 337–340

doi: 10.1097/ACI.0b013e328355b8f5

DRUG ALLERGY: Edited by Bernard Thong and Miguel Blanca


Progress in understanding hypersensitivity drug reactions: an overview



Blanca, Miguela; Thong, Bernardb




Free Access





Article Outline


Collapse Box

Author Information





aAllergy Service, Carlos Haya Hospital, Hospital Civil, Malaga, Spain

bDepartment of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore

Correspondence to Miguel Blanca, MD, PhD, Pabellon 5, Planta sótano. E-mail: miguel.blanca.sspa@juntadeandalucia.es










Thursday, September 19, 2013

0 Testing for Drug Hypersensitivity Syndromes


Logo of clinbiorev








Clin Biochem Rev. 2013 February; 34(1): 15–38.





PMCID: PMC3626363





Testing for Drug Hypersensitivity Syndromes



Craig M Rive,1 Jack Bourke,2 and Elizabeth J Phillips1–4*







Abstract



Adverse drug reactions are a common cause of patient morbidity and mortality. Type B drug reactions comprise only 20% of all drug reactions but they tend to be primarily immunologically mediated and less dependent on the drug’s pharmacological action and dose. Common Type B reactions seen in clinical practice are those of the immediate, IgE, Gell-Coombs Type I reactions, and the delayed, T-cell mediated, Type IV reactions. Management of these types of reactions, once they have occurred, requires careful consideration and recognition of the utility of routine diagnostic tests followed by ancillary specialised diagnostic testing. For Type I, IgE mediated reactions this includes prick/intradermal skin testing and oral provocation. For Type IV, T-cell mediated reactions this includes a variety of in vivo(patch testing) and ex vivo tests, many of which are currently mainly used in highly specialised research laboratories. The recent association of many serious delayed (Type IV) hypersensitivity reactions to specific drugs with HLA class I and II alleles has created the opportunity for HLA screening to exclude high risk populations from exposure to the implicated drug and hence prevent clinical reactions. For example, the 100% negative predictive value of HLA-B*5701 for true immunologically mediated abacavir hypersensitivity and the development of feasible, inexpensive DNA-based molecular tests has led to incorporation of HLA-B*5701 screening in routine HIV clinical practice. The mechanism by which drugs specifically interact with HLA has been recently characterised and promises to lead to strategies for pre-clinical screening to inform drug development and design.





Formats:







Tuesday, September 17, 2013

0 Severe dapsone hypersensitivity syndrome in a child













CASE REPORT

Korean J Pediatr 2013 June;56(6) :260-264.
Published online 2012 October 25.        doi:http://dx.doi.org/10.3345/kjp.2013.56.6.260



































Severe dapsone hypersensitivity syndrome in a child
So Yoon Choi1, Ho Yeon Hwang1, Jung Hyun Lee1, Jae Sun Park1, Min Soo Jang2
1Departments of Pediatrics Kosin University Gospel Hospital, Busan, Korea
2Departments of Dermatology, Kosin University Gospel Hospital, Busan, Korea
Corresponding Author: Jae Sun Park ,Tel: +82-51-990-6230, Fax: +82-51-990-3005, Email: pjs@ns.kosinmed.or.kr
Copyright © 2013 by The Korean Pediatric Society
Share :   
ABSTRACT
Dapsone (4,4′-diaminodiphenylsulfone, DDS), a potent anti-inflammatory agent, is widely used in the treatment of leprosy and several chronic inflammatory skin diseases. Dapsone therapy rarely results in development of dapsone hypersensitivity syndrome, which is characterized by fever, hepatitis, generalized exfoliative dermatitis, and lymphadenopathy. Here, we describe the case of an 11-year-old Korean boy who initially presented with high fever, a morbilliform skin rash, generalized lymphadenopathy, hepatosplenomegaly, and leukopenia after 6 weeks of dapsone intake. Subsequently, he exhibited cholecystitis, gingivitis, colitis, sepsis, aseptic meningitis, disseminated intravascular coagulation, syndrome of inappropriate antidiuretic hormone secretion, pneumonia, pleural effusions, peritonitis, bronchiectatic changes, exfoliative dermatitis, and acute renal failure. After 2 months of supportive therapy, and prednisolone and antibiotic administration, most of the systemic symptoms resolved, with the exception of exfoliative dermatitis and erythema, which ameliorated over the following 4 months. Agranulocytosis, atypical lymphocytosis, aseptic meningitis, and bronchiectatic changes along with prolonged systemic symptoms with exfoliative dermatitis were the most peculiar features of the present case.

Keywords: Aseptic meningitis | Bronchiectasis | Dapsone | Multiple organ failure







































TOOLS
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
Supplementary Material  Supplementary Material
  E-Mail